StockData

Codexis vs Gevo

CDXS and GEVO side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CDXS and GEVO compare

Gevo is the larger company, worth 3.5 times as much as Codexis ($405M against $117M).

Gevo grew revenue faster over the last twelve months (121% versus 35.9% for Codexis).

Codexis keeps more of each dollar of sales as profit, with a net margin of −39.6% compared with −120% at Gevo.

Gevo scores higher on the StockData Score (8 against 4 for Codexis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCDXSGEVO
Size and price
Market cap$117M$405M
Share price$1.07$1.64
Change, 1 year−35.0%−16.8%
Change, 5 years−97.1%−71.5%
Beta (5Y)2.46−0.22
Employees146151
StockData Score
Total score48 (better)
Valuation score02 (better)
Growth score24 (better)
Performance score11
Health score11
Dividend score00
Valuation
P/S1.5× (better)2.3×
P/B3.6×1.5× (better)
FCF yield−10.4% (better)−14.0%
Fair value$1.07$2.40
Margin of safety−0.41%31.5% (better)
Growth
Revenue growth (TTM)35.9%121% (better)
Revenue growth, 5Y average0.38%96.1% (better)
Profitability
Gross margin87.0% (better)47.3%
Operating margin−35.6% (better)−103%
Net margin−39.6% (better)−120%
FCF margin−15.7% (better)−31.9%
Return on equity−69.4%−57.0% (better)
Return on invested capital−91.8%−29.8% (better)
Financial health
Debt / equity1.240.61 (better)
Interest coverage–−8.8×
Current ratio3.06 (better)2.70
Altman Z-score−6.14−2.50 (better)
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions63.7%37.2%
Held by insiders2.2%4.8%
Insider net buying, 12 months−$899K (better)−$2.5M
Short interest, % of float4.1%10.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.